US 11,773,166 B2
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
Romain Ollier, La Chaux-de-Fonds (CH); Samuel Hou, La Chaux-de-Fonds (CH); Rami Lissilaa, La Chaux-de-Fonds (CH); Darko Skegro, La Chaux-de-Fonds (CH); and Jonathan Back, La Chaux-de-Fonds (CH)
Assigned to Ichnos Sciences SA, La Chaux-de Fonds (CH)
Filed by Ichnos Sciences SA, La Chaux-de-Fonds (CH)
Filed on Oct. 12, 2018, as Appl. No. 16/159,231.
Application 16/159,231 is a continuation of application No. 15/524,485, abandoned, previously published as PCT/EP2015/075628, filed on Nov. 3, 2015.
Claims priority of application No. 15167034 (EP), filed on May 8, 2015.
Prior Publication US 2019/0135918 A1, May 9, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 38/00 (2006.01)
CPC C07K 16/2809 (2013.01) [A61P 35/00 (2018.01); C07K 16/2896 (2013.01); A61K 38/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/524 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/94 (2013.01)] 12 Claims
 
1. A bispecific antibody or fragment thereof that binds to human CD38 comprising a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 25 or SEQ ID NO: 208, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 26 or SEQ ID NO: 209, and a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 27 or SEQ ID NO: 210; and comprising a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 28 or SEQ ID NO: 211 or SEQ ID NO: 214, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 29 or SEQ ID NO: 212, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 30 or SEQ ID NO: 213.